| Bristol-Myers Squibb Company (BMY) | |||
|---|---|---|---|
| 67.68 0.7 (1.05%) | 03-24 16:00 | ||
| Open: | 67.2 | Pre. Close: | 66.98 |
| High: | 67.775 | Low: | 66.69 |
| Volume: | 6,058,833 | Market Cap: | 142,045(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 81.08 One year: 84.07 |
| Support: | Support1: 65.28 Support2: 54.31 |
| Resistance: | Resistance1: 69.42 Resistance2: 71.98 |
| Pivot: | 67.11  |
| Moving Averages: | MA(5): 67.33 MA(20): 67.67 MA(100): 73.51 MA(250): 73.78 |
| MACD: | MACD(12,26): -1.02 Signal(12,26,9): -1.23 |
| %K %D: | %K(14,3): 45.92 %D(3): 45.09 |
| RSI: | RSI(14): 44.27 |
| 52-Week: | High: 81.44 Low: 65.28 Change(%): -8.2 |
| Average Vol(K): | 3-Month: 8118 10-Days: 9262 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 67.814 - 68.148 | 68.148 - 68.487 |
| Low: | 65.898 - 66.247 | 66.247 - 66.601 |
| Close: | 67.118 - 67.672 | 67.672 - 68.233 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BMY ] has closed below upper band by 31.6%. Bollinger Bands are 47.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers—General | |
| Shares Out. (M) | 2100.00 |
| Shares Float (M) | 2100.00 |
| % Held by Insiders | 0.07 |
| % Held by Institutions | 78.84 |
| Shares Short (K) | 17020 |
| Shares Short Prior Month (K) | 20720 |
| Stock Financials | |
|---|---|
| EPS | 2.910 |
| Book Value (p.s.) | 14.810 |
| Profit Margin | 13.71 |
| Operating Margin | 21.40 |
| Return on Assets (ttm) | 6.0 |
| Return on Equity (ttm) | 18.9 |
| Qtrly Rev. Growth | -4.8 |
| Gross Profit (p.s.) | 17.324 |
| Sales Per Share | 21.981 |
| EBITDA (p.s.) | 9.600 |
| Qtrly Earnings Growth | -11.40 |
| Operating Cash Flow (M) | 13070.00 |
| Levered Free Cash Flow (M) | 13830.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 23.26 |
| PEG Ratio | 2.05 |
| Price to Book value | 4.57 |
| Price to Sales | 3.08 |
| Price to Cash Flow | 10.87 |
| Stock Dividends | |
|---|---|
| Dividend | 0.570 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
